Susan Galbraith, AstraZeneca EVP, oncology R&D

Claim­ing his­toric first, As­traZeneca says En­her­tu aces PhI­II for hard-to-reach seg­ment of pa­tients

As­traZeneca has racked up a cru­cial Phase III win for its megablock­buster prospect En­her­tu — one that could push the drug to un­char­tered places cur­rent­ly un­reach­able for its peers.

For a while now, the phar­ma gi­ant has been talk­ing about how its third-gen an­ti­body drug con­ju­gate, de­vel­oped in a $6.9 bil­lion part­ner­ship with Dai­ichi Sankyo, could do a bet­ter job go­ing af­ter tu­mors marked by var­i­ous lev­els of HER2 ex­pres­sion — even those that would tra­di­tion­al­ly be de­scribed as “HER2-low.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.